Compare ELME & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELME | MOLN |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 170.5M |
| IPO Year | 1994 | 2021 |
| Metric | ELME | MOLN |
|---|---|---|
| Price | $1.75 | $3.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 1.1M | 1.7K |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 838.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $206,360,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.13 | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $3.53 |
| 52 Week High | $17.68 | $5.36 |
| Indicator | ELME | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 42.29 |
| Support Level | $1.62 | $3.79 |
| Resistance Level | $2.06 | $4.39 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 92.86 | 6.19 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.